Webinar
18 May 2026
Mind the Loss: Formulation optimization reduces cannula-associated vector loss during precision AAV brain delivery
In this poster presented at ASGCT 2026, Philipp Beck explores how formulation optimization can reduce vector loss during direct...
Read More18 May 2026
Lentiviral Vector Purification: Optimizing the Downstream Chromatography Step
In this presentation from ASGCT 2026, Shanshan Zhu shares new insights into optimizing anion exchange chromatography for lentiviral vector...
Read More18 May 2026
Not all reads are created equal: correcting the size bias in rAAV nanopore sequencing data
In this presentation from ASGCT 2026, Kathrin Breunig explains how Ascend is improving the accuracy of Oxford Nanopore sequencing...
Read More25 March 2026
Why learning from past mistakes is more important than ever
In this presentation, we explore why gene therapy must learn from its past to unlock its future. Drawing on...
Read More8 January 2026
Ascend Advanced Therapies – ABL Inc. Further Strengthens Executive Team As It Drives Forward An Ambitious Growth Strategy
Rockville, Maryland – 8 January 2026 – Ascend Advanced Therapies – ABL Inc. today announced significant appointments to its...
Read More24 November 2025
Advancing rAAV Characterization with Oxford Nanopore Sequencing
In this recorded webinar hosted by Oxford Nanopore Technologies, scientists from Ascend Advanced Therapies discuss how they have implemented Oxford Nanopore...
Read More10 November 2025
Ascend Unveils Proprietary Enhancers That Significantly Improve AAV Yields Without Compromising Quality
New data from Ascend’s R&D team demonstrate up to 3-fold increase in AAV yields supporting greater efficiency and scalability...
Read More5 November 2025
Ascend Advanced Therapies Identifies microRNAs That Enhance AAV Vector Production
Screen of more than 2,400 microRNAs identifies multiple candidates that significantly enhance vector productivity without compromising quality attributes. Munich,...
Read More8 October 2025
European Patent on Ascend Advanced Therapies’ EpyQ® AAV Plasmid Technology Successfully Defended at the EPO
Rockville, Maryland – 8th October, 2025 – Ascend Advanced Therapies (Ascend), a gene-to-GMP development partner, today announced that its...
Read More28 July 2025
Performance Evaluation of the ABL p24 ELISA Kit for Accurate Lentiviral Vector Titer Determination in Cell and Gene Therapy Applications
The ABL p24 ELISA kit, originally developed for HIV titer determination, has evolved into a critical tool for the...
Read More2 July 2025
The Final Mile: Why Fill/Finish Operations Make or Break Viral Vector Therapies
After years of groundbreaking research and millions in development costs, the future of a revolutionary gene therapy can come...
Read More10 June 2025
Ascend Completes GMP Certification for Quality Control Testing in Munich Facility
Rockville, Maryland – 10 June 2025 – Ascend Advanced Therapies (Ascend), a gene-to-GMP development partner, has received GMP certification...
Read More